Related references
Note: Only part of the references are listed.Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer
Ilaria Alborelli et al.
JOURNAL OF PATHOLOGY (2020)
Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus Vinorelbine Plus Cisplatin for Completely Resected Stage II to IIIA Nonsquamous Non-Small-Cell Lung Cancer
Hirotsugu Kenmotsu et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC
D. Ross Camidge et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Mutational burden and signatures in 4000 Japanese cancers provide insights into tumorigenesis and response to therapy
Keiichi Hatakeyama et al.
CANCER SCIENCE (2019)
In-House Implementation of Tumor Mutational Burden Testing to Predict Durable Clinical Benefit in Non-Small Cell Lung Cancer and Melanoma Patients
Simon Heeke et al.
CANCERS (2019)
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
The Tumor Mutational Burden of Chinese Advanced Cancer Patients Estimated by a 381-cancer-gene Panel
Wu Zhuang et al.
JOURNAL OF CANCER (2018)
Tumor Mutation Burden as a Biomarker in Resected Non-Small-Cell Lung Cancer
Siddhartha Devarakonda et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
A scalable solution for tumor mutational burden from formalinfixed, paraffin-embedded samples using the Oncomine Tumor Mutation Load Assay
Ruchi Chaudhary et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2018)
Mutational signatures associated with tobacco smoking in human cancer
Ludmil B. Alexandrov et al.
SCIENCE (2016)
Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
Michael S. Rooney et al.
CELL (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial
Gunter von Minckwitz et al.
LANCET ONCOLOGY (2014)
Hypermutation in human cancer genomes: footprints and mechanisms
Steven A. Roberts et al.
NATURE REVIEWS CANCER (2014)
Anaplastic Lymphoma Kinase Translocation A Predictive Biomarker of Pemetrexed in Patients with Non-small Cell Lung Cancer
Jeong-Ok Lee et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Lung Adjuvant Cisplatin Evaluation: A pooled analysis by the LACE collaborative group
Jean-Pierre Pignon et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Current status of excision repair cross complementing-group 1 (ERCC1) in cancer
Lucy Gossage et al.
CANCER TREATMENT REVIEWS (2007)
Epidermal growth factor receptor mutation status and adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung
Hiroshi Suehisa et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Schedule-dependent interactions between pemetrexed and cisplatin in human carcinoma cell lines in vitro
Y Kano et al.
ONCOLOGY RESEARCH (2006)
Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways
R Sordella et al.
SCIENCE (2004)
Apoptosis and p53 status predict the efficacy of postoperative administration of UFT in non-small cell lung cancer
F Tanaka et al.
BRITISH JOURNAL OF CANCER (2001)
Share Paper
